![](https://monteverdelaw.com/wp-content/uploads/1640136249767.png)
Alpine Immune Sciences, Inc. (Nasdaq: ALPN), relating to its proposed sale to Vertex Pharmaceuticals Inc.. Under the terms of the agreement, ALPN shareholders are expected to receive $65.00 in cash per share they own.
Alpine Immune Sciences, Inc. (Nasdaq: ALPN), relating to its proposed sale to Vertex Pharmaceuticals Inc.. Under the terms of the agreement, ALPN shareholders are expected to receive $65.00 in cash per share they own.